Skip to content

Patient experience and advocacy

Ethics. This page synthesises public, peer-reviewed qualitative research and verified organisation websites in aggregate. No private individual is named, no patient quotation is reproduced, and no narrative is assembled about any identifiable person. Method and full source accounting are in literature/patient-voice/README.md.

TL;DR — The largest synthesis of this literature — 126 papers reporting 102 studies with 3,095 participants — found that stigma, normalisation of symptoms and lack of knowledge are consistent barriers to diagnosis, and that the most reported gap is specialist support after diagnosis (Bunn 2012, PMID 23118618). A review of 35 papers covering 373 people with early-stage dementia found struggles with self-identity, independence, control, status, activities, stigma and how to view the future, with widespread dissatisfaction about how the diagnosis was communicated and insufficient information afterwards — a diagnosis process that may itself disempower (Low 2018, PMID 28828999). Younger people carry an additional layer: delays attributed to late help-seeking and clinician misattribution of symptoms, reactions ranging from reassurance to destabilisation depending heavily on the clinician's language, and stigma operating at public, structural and social-isolation levels across 17 studies (O'Malley 2021, PMID 31647324; Lowe 2026, PMID 42478735). Advance care planning is wanted and dreaded simultaneously: across 84 studies involving 389 people with dementia and 1,864 carers, themes included avoiding dehumanising care, confronting emotionally difficult conversations, navigating existential tensions, defining personal autonomy, and lacking confidence in healthcare settings (Sellars 2019, PMID 30404576). Caregivers are a distinct population with measurable harm — depression effect size g=0.58 versus non-caregivers, pooled anxiety prevalence 32.1% (Pinquart 2003, PMID 12825775; Kaddour 2020, PMID 31409196).

What the qualitative evidence establishes

Diagnosis is a process, not an event

Bunn's thematic synthesis identified three overarching themes across 102 studies: pathways through diagnosis, including its impact on identity, roles and relationships; resolving conflicts to accommodate a diagnosis, including the acceptability of support, the choice between focusing on the present or the future, and the use or avoidance of knowledge; and strategies to minimise the impact of dementia. Barriers to earlier diagnosis were consistent — stigma, normalisation of symptoms, and lack of knowledge — and the recurrent service gap was specialist support post-diagnosis (Bunn 2012, PMID 23118618).

The authors' recommendation in 2012 was that research emphasis shift from describing experience to developing and evaluating post-diagnostic support interventions. Fourteen years later, the largest such trial found no effect on behavioural symptoms or caregiver strain from either health-system or community-based dementia care versus usual care, while improving caregiver self-efficacy — see care, caregiving and health systems.

The diagnosis process can itself do harm

Low's review tested the "Prescribed Disengagement®" hypothesis — that post-diagnostic advice implicitly tells people to slow down and withdraw. Across 35 papers and 373 participants, the review did not support the claim that disengagement is explicitly prescribed, but concluded that it may be implied by the diagnosis process and by inadequate post-diagnostic support, and that this "may have contributed to disempowerment of the person with dementia, made it more difficult to accept the diagnosis, and exacerbated negative views and self-stigma" (Low 2018, PMID 28828999). Many studies reported dissatisfaction with how the diagnosis was communicated, insufficient information about dementia, and limited treatments and support offered.

This is a precise and useful finding: the harm is attributed to omission and framing rather than to explicit advice, which makes it a modifiable feature of clinical communication rather than an inherent consequence of knowing.

Young-onset dementia is a different experience, not a younger version of the same one

Domain Finding
Diagnostic delay Attributed to (1) delays in accessing help and (2) misattribution of symptoms by the clinician; the impact of diagnosis was strongly influenced by the clinician's use of language, with reactions ranging from reassurance that symptoms were finally explained, to shock and destabilisation (O'Malley 2021, PMID 31647324)
Identity Four themes across a meta-synthesis: declining cognition and a prolonged diagnostic process threaten self-identity; struggling to accept diagnosis and maintain identity; maintaining identity and normalcy through social support and person-centred care; and self-development and identity reshaping at later stages. Only five eligible publications were found (Tang 2023, PMID 37646673)
Stigma Seventeen studies, four themes: public perception and beliefs about YOD; structural stigma and barriers to service access; the role of stigma in social isolation; and overcoming stigma. The review calls for age-appropriate specialist services alongside public and professional education (Lowe 2026, PMID 42478735)
Driving cessation Eighteen in-depth interviews (10 people with YOD, 8 family caregivers): losses and burdens; the unique challenges of YOD; coping and adjustment; how to meet needs. Driving disruption arrives when people have significant financial and family commitments and may still be employed or raising children, damaging roles and self-identity (Scott 2023, PMID 37481262)

The epidemiology behind this — global age-standardised YOD prevalence 119.0 per 100,000 in ages 30–64, about 3.9 million people, with incidence around 11 per 100,000 — is on epidemiology and burden, and the atypical phenotypes over-represented in young-onset disease are on clinical presentation and staging.

Advance care planning: wanted, difficult, and rarely done

Fewer than 40% of people with dementia undertake advance care planning internationally. Synthesis of 84 studies (389 people with dementia, 1,864 carers) produced five themes (Sellars 2019, PMID 30404576):

  1. Avoiding dehumanising treatment and care — remaining connected, delaying institutionalisation, rejecting the burdens of futile treatment.
  2. Confronting emotionally difficult conversations — signifying death, unpreparedness to face impending cognitive decline, feeling locked into a pathway.
  3. Navigating existential tensions — accepting inevitable incapacity and death, fear of being responsible for the cause of death, alleviating decisional responsibility.
  4. Defining personal autonomy — struggling with unknown preferences, depending on carer advocacy, justifying treatments for health deteriorations.
  5. Lacking confidence in healthcare settings — distrusting clinicians' mastery and knowledge, making uninformed choices, being deprived of hospice access and end-of-life support.

The third theme is the one most often missed by service design: carers describe fear of being responsible for causing death, and a wish to have decisional responsibility lifted from them. The corresponding trial evidence — that advance care planning interventions reliably increase documentation and goals-of-care discussions but have not been shown to change symptom experience — is on care, caregiving and health systems.

Access is unequal, and the reasons are cultural as well as structural

A systematic review of pathways to care found barriers in minority ethnic groups including not conceptualising dementia as an illness, believing it a normal consequence of ageing, attributing it to spiritual, psychological, physical or social causes, treating care as a personal or family responsibility, shame and stigma within the community, believing nothing could be done, and negative prior experiences of healthcare. Recognising dementia as an illness and knowing about it facilitated help-seeking (Mukadam 2011, PMID 21157846).

A meta-synthesis of 18 studies of older immigrants living with dementia found five synthesised themes — living with dementia and caregiving, family relationships, barriers to dementia care services, stigma and discrimination, and legal and financial issues — and concluded that there was "very little difference between the experiences of those who have migrated to a new country and those who were born and aged in the same country, but the ability to access and use the available services is different" (Chejor 2022, PMID 35613772). Culturally-specific work in Vietnam and the Vietnamese diaspora (Nguyen 2023, PMID 35549573) and in under-served geographical areas (Kay 2026, PMID 42341205) extends the same pattern.

This maps directly onto the quantitative disparity data: missed or delayed clinical diagnosis in 41% of non-Hispanic White, 46% of non-Hispanic Black and 54% of Hispanic participants, with mean delays of 31.2, 34.6 and 43.8 months (epidemiology and burden).

LMIC evidence exists, but is geographically scattered and rarely patient-led

The audit's live search corrected an overbroad claim that LMIC qualitative evidence was almost absent. In Colombia, interviews with 20 people with AD and 24 caregivers found that illness awareness was shaped by personality, prior experience, socioeconomic conditions and social support (Ramos 2026, PMID 41717228). Studies of caregivers in Iran and rural or south-western Uganda identified a support ecology spanning family, community and religious leaders, alongside fragmented formal support and financial, physical and psychological burden (Sadeghi-Mahalli 2025, PMID 39097934; Abaasa 2023, PMID 37680685; Ainamani 2020, PMID 33043153). Malaysian providers described existing but poorly connected services, late presentation, workforce constraints and families carrying most post-diagnostic care (Goodson 2021, PMID 34368037).

These studies establish that evidence exists; they do not answer what people with dementia across LMICs prioritise. Four of the five are caregiver-, provider- or dyad-centred, the countries are not a representative sample, and no cross-country patient-led priority-setting study was retrieved.

Caregivers

Caregiver harm is quantified rather than qualitative: depression g=0.58, stress g=0.55, self-efficacy g=0.54 and subjective well-being g=−0.40 versus non-caregivers, with larger differences for dementia caregiving than for mixed caregiver samples (Pinquart 2003, PMID 12825775), and pooled anxiety prevalence of 32.1% (95% CI 20.6–46.2) (Kaddour 2020, PMID 31409196). REACH II showed this is modifiable — clinical depression 12.6% versus 22.7% (P=0.001) after a structured multicomponent intervention delivered across three racial/ethnic groups (Belle 2006, PMID 17116917).

Burden is not the whole experience. An integrative review of 41 studies identified four positive domains: personal accomplishment and gratification, mutuality in the dyad, family cohesion and personal growth (Yu 2018, PMID 29128685). A separate 17-study synthesis found gratitude and the ability to find meaning associated with caregiver sense of competence, alongside negative influences from depression and behavioural symptoms (van der Lee 2019, PMID 30466499). Positive meaning can coexist with substantial harm; it should not be used to minimise support needs.

The period around diagnosis carries measurable risk

Suicide risk is elevated in the first year after diagnosis (SMR 1.53, 95% CI 1.42–1.65; 3.40 at ages 65–74; highest in the first 90 days) and after a recent MCI diagnosis (adjusted HR 1.73, 95% CI 1.34–2.22) (Schmutte 2022, PMID 34036738; Günak 2021, PMID 33760039). Read alongside the qualitative finding that the manner of disclosure shapes whether people feel reassured or destabilised (O'Malley 2021, PMID 31647324), this makes disclosure communication a safety intervention, not only a courtesy. See red flags and safety concerns.

Organisations

Every organisation below was rechecked on 2026-08-31. Twelve sites returned content directly; Alzheimer's Disease International returned HTTP 403 to command-line retrieval but its official homepage and member directory were current in the live web index. A successful check establishes a live public presence and the described functions; it does not verify charitable registration, service quality or national reach. Fetch failures are recorded in literature/patient-voice/organizations.md.

Organisation Region Publicly visible functions
Alzheimer's Disease International (ADI) Global federation Works with associations in over 100 countries; World Alzheimer Report series; World Alzheimer's Month campaign; member accreditation; advocacy toolkits; annual conference
Dementia Alliance International (DAI) Global, membership restricted to people with a diagnosis of dementia Peer support groups run by and for people with dementia; webinars and Brain Health Hub; human-rights and disability advocacy submissions; member blogs; advocacy award
Alzheimer Europe Europe (umbrella of 44 associations in 39 countries) EU and national policy work; European Working Group of People with Dementia; European Dementia Carers Working Group; Dementia in Europe magazine; anti-stigma award
Alzheimer's Association United States 24/7 helpline in over 200 languages; care consultations, support groups and education; research funding; federal advocacy; Facts and Figures publication
Alzheimer's Society United Kingdom Dementia Support Line; online Dementia Support Forum; research; policy campaigning; public personal-story content
Alzheimer's Research UK United Kingdom Dementia research funding and researcher support; public dementia information; awareness campaigns
Alzheimer Society of Canada Canada Information for people worried about dementia, people living with dementia and carers; First Link® connection programme; national dementia guidelines and communication toolkit; research programme; local chapter directory
Dementia Australia Australia National Dementia Helpline (24/7); post-diagnostic counselling, peer support and Memory Lane Cafes; Dementia Advocates Program; dementia-friendly communities; research foundation; lived-experience podcast
認知症の人と家族の会 (Alzheimer's Association Japan) Japan ~9,000 members across all 47 prefectures; telephone counselling; peer gatherings (tsudoi); newsletter; children's dementia-education site; policy declarations
CEAFA (Confederación Española de Alzheimer) Spain Association network for local access; research promotion; "Pacto por el Recuerdo" political advocacy; national congresses; training programmes; publications
ABRAz (Associação Brasileira de Alzheimer) Brazil Regional chapters; Portuguese-language educational content and video series; Brazilian Alzheimer Congress; public-policy advocacy; family and caregiver guidance
DementiaSA South Africa Virtual help and support; counselling groups; caregiver training courses; advice sheets and speaking books; awareness content
ADASA (Association for Dementia and Alzheimer's of South Africa) South Africa (9 provinces) Support groups led by staff or trained volunteers; psycho-social support, counselling and family consultation; educational materials; webinars and community events

Two structural observations. First, DAI is the only organisation in this list whose membership is restricted to people who have dementia themselves — most other bodies represent people with dementia, families and professionals together, which shapes whose priorities dominate. Second, the regions with the largest projected increases in dementia — north Africa and the Middle East (+367%) and eastern sub-Saharan Africa (+357%) — are almost absent from this list; that reflects this build's English-language search and fetch reach as much as the underlying organisational landscape, and is recorded as a coverage limit rather than a finding.

Young-onset evidence is specific enough to change service design

An Australian qualitative study interviewed 14 people with young-onset dementia and 28 family caregivers across metropolitan, regional and rural settings. The diagnostic journey combined gradual worsening, drawn-out investigation and reluctance to confront dementia; receiving the diagnosis produced shock and devastation for some, but confirmation and relief for others (Lai 2023, PMID 37126513). The contradiction is substantive: faster disclosure is not automatically kinder unless post-diagnostic support arrives with it.

A systematic review of 19 studies on biological relatives—mostly children of a parent with young-onset dementia—identified disrupted family functioning, varied emotional impact, uncertainty about caregiving and inherited risk, lack of visibility in health care and society, and coping through distancing or emotion-focused strategies (Wiggins 2023, PMID 36516659). This is not interchangeable with spouse-caregiver evidence in late-onset AD: the family member may simultaneously be a caregiver, dependent child and person at genetic risk.

Biomarker-era experience remains thinner, but it is no longer absent. In a 30-patient urban memory-centre case series, amyloid PET revised 10 diagnoses and clarified nine, sometimes preventing inappropriate treatment or trial referral (Mitsis 2014, PMID 24484858) — decision impact, not patient-reported benefit. Two qualitative studies now report on anti-amyloid therapy itself. Semi-structured interviews with 22 people with biomarker- or imaging-confirmed AD who had discussed lecanemab with a clinician (mean age 70, 36% women, 100% White) found information sought from advocacy organisations, the internet and clinicians; hope and the existential threat of dementia driving readiness to start; and risk–benefit weighing shaped by family, insurance coverage and trust in expertise — with some accepting treatment at any cost and a few concluding that costs outweighed benefit. Participants wanted more individualised information and to hear from people who had taken the drug (Parks 2025, PMID 40207637). Interviews with 22 Japanese care partners about donanemab and the treat-to-clearance approach found mental burden and time constraints, relief at confirmed plaque clearance, expectation that stopping would save waiting time and money, and continuing worry about progression and follow-up after stopping (Katayama 2026, PMID 41307609). Both study populations are people considering or supporting treatment. A live PubMed search on 2026-09-03 returned no qualitative study of the treatment period itself — infusion burden, surveillance MRI, or the experience of an ARIA event — so that narrower gap remains open.

What patient-voice evidence can and cannot do

  • It identifies priorities and harms that outcome scales miss: identity, disempowerment at diagnosis, structural stigma, decisional burden at end of life.
  • It does not establish treatment efficacy. A testimonial cannot substitute for a trial, and this knowledge base does not use it that way.
  • Qualitative synthesis establishes recurring patterns and mechanisms, not prevalence. The prevalence figures on this page (32.1% caregiver anxiety, <40% undertaking advance care planning, SMR 1.53) come from quantitative sources.
  • The people least able to participate in interview-based research — those with advanced dementia, severe communication impairment, or no English — are systematically under-represented in every synthesis cited here.

Open questions

  • Does changing how a diagnosis is communicated change outcomes, given that the manner of disclosure recurs as the strongest modifiable theme (Low 2018, PMID 28828999; O'Malley 2021, PMID 31647324)?
  • Would age-appropriate specialist services for young-onset dementia reduce stigma and isolation, as the reviews recommend, and by how much (Lowe 2026, PMID 42478735; Tang 2023, PMID 37646673)?
  • Can advance care planning be redesigned around the carer's fear of "being responsible for cause of death" rather than around documentation targets (Sellars 2019, PMID 30404576)?
  • Why is the immigrant experience of living with dementia similar to the native-born experience while access differs so sharply, and which access barrier is most tractable (Chejor 2022, PMID 35613772; Mukadam 2011, PMID 21157846)?
  • What would biomarker-era disclosure — telling an asymptomatic person they have a biologically defined disease — do to identity and disengagement, given what the syndromic-diagnosis literature shows (Low 2018, PMID 28828999; see diagnostic criteria)?
  • What do people with dementia in low- and middle-income countries prioritise, beyond the caregiver-, provider- and dyad-centred evidence retrieved from Colombia, Iran, Uganda and Malaysia (Ramos 2026, PMID 41717228; Sadeghi-Mahalli 2025, PMID 39097934; Abaasa 2023, PMID 37680685; Ainamani 2020, PMID 33043153; Goodson 2021, PMID 34368037)?
  • Does the fact that only one major international organisation is led exclusively by people with dementia change which priorities reach policy?

References

  1. Bunn F, et al. Psychosocial factors that shape patient and carer experiences of dementia diagnosis and treatment: a systematic review of qualitative studies. PLoS Med. 2012;9:e1001331. PMID 23118618.
  2. Low LF, et al. Do people with early stage dementia experience Prescribed Disengagement®? A systematic review of qualitative studies. Int Psychogeriatr. 2018;30:807-831. PMID 28828999.
  3. O'Malley M, et al. Receiving a diagnosis of young onset dementia: a scoping review of lived experiences. Aging Ment Health. 2021;25:1-12. PMID 31647324.
  4. Tang X, et al. Lived experiences of maintaining self-identity among persons living with young-onset dementia: a qualitative meta-synthesis. Dementia (London). 2023;22:1776-1798. PMID 37646673.
  5. Lowe F, et al. The experience of stigma within the young onset dementia (YOD) population: a systematic review of qualitative research. Health Expect. 2026;29:e70773. PMID 42478735.
  6. Scott TL, et al. A qualitative study exploring the experiences and needs of people living with young onset dementia related to driving cessation. Age Ageing. 2023;52. PMID 37481262.
  7. Sellars M, et al. Perspectives of people with dementia and carers on advance care planning and end-of-life care: a systematic review and thematic synthesis of qualitative studies. Palliat Med. 2019;33:274-290. PMID 30404576.
  8. Mukadam N, et al. A systematic review of ethnicity and pathways to care in dementia. Int J Geriatr Psychiatry. 2011;26:12-20. PMID 21157846.
  9. Chejor P, et al. Experiences of older immigrants living with dementia and their carers: a systematic review and meta-synthesis. BMJ Open. 2022;12:e059783. PMID 35613772.
  10. Nguyen TA, et al. Experiences and perceptions of dementia in Vietnam and among the Vietnamese diaspora: a systematic review of qualitative studies. Aging Ment Health. 2023;27:301-316. PMID 35549573.
  11. Kay J, et al. The experiences of living with dementia within an under-served geographical area: a systematic review and qualitative synthesis. Age Ageing. 2026;55. PMID 42341205.
  12. Pinquart M, et al. Differences between caregivers and noncaregivers in psychological health and physical health: a meta-analysis. Psychol Aging. 2003;18:250-67. PMID 12825775.
  13. Kaddour L, et al. Anxiety in informal dementia carers: a meta-analysis of prevalence. J Geriatr Psychiatry Neurol. 2020;33:161-172. PMID 31409196.
  14. Belle SH, et al. Enhancing the quality of life of dementia caregivers from different ethnic or racial groups: a randomized, controlled trial. Ann Intern Med. 2006;145:727-38. PMID 17116917.
  15. Schmutte T, et al. Suicide risk in first year after dementia diagnosis in older adults. Alzheimers Dement. 2022;18:262-271. PMID 34036738.
  16. Günak MM, et al. Risk of suicide attempt in patients with recent diagnosis of mild cognitive impairment or dementia. JAMA Psychiatry. 2021;78:659-666. PMID 33760039.
  17. Ramos C, et al. Understanding illness awareness in Alzheimer's disease: a qualitative study with patient-caregiver dyads in Colombia. Front Aging Neurosci. 2026;18:1748863. PMID 41717228.
  18. Sadeghi-Mahalli F, et al. Factors affecting support: experiences of Iranian older spousal caregivers of people with Alzheimer's disease and their support resources. Aging Ment Health. 2025;29:423-432. PMID 39097934.
  19. Abaasa C, et al. A qualitative investigation of the psychosocial services utilised by care-givers of patients with Alzheimer's disease and related dementias in southwestern Uganda. Ageing Soc. 2023. PMID 37680685.
  20. Ainamani HE, et al. Caring for people with dementia in rural Uganda: qualitative study of caregiving burden experienced by informal and formal caregivers. J Glob Health Rep. 2020;4:e2020049. PMID 33043153.
  21. Goodson ML, et al. A qualitative study on formal and informal carers' perceptions of dementia care provision and management in Malaysia. Front Public Health. 2021;9:637484. PMID 34368037.
  22. Yu DSF, et al. Unravelling positive aspects of caregiving in dementia: an integrative review of research literature. Int J Nurs Stud. 2018;79:1-26. PMID 29128685.
  23. van der Lee J, et al. Factors related to sense of competence in family caregivers of people living with dementia in the community: a narrative synthesis. Int Psychogeriatr. 2019;31:799-813. PMID 30466499.
  24. Lai M, et al. Journey to diagnosis of young-onset dementia: a qualitative study of people with young-onset dementia and their family caregivers in Australia. Dementia (London). 2023;22:1097-1114. PMID 37126513.
  25. Wiggins M, et al. Young-onset dementia: a systematic review of the psychological and social impact on relatives. Patient Educ Couns. 2023;107:107585. PMID 36516659.
  26. Mitsis EM, et al. A consecutive case series experience with florbetapir PET imaging in an urban dementia center. Mol Neurodegener. 2014;9:10. PMID 24484858.
  27. Parks AL, et al. A qualitative study of people with Alzheimer's disease in a memory clinic considering lecanemab treatment. J Alzheimers Dis. 2025;105:494-504. PMID 40207637.
  28. Katayama S, et al. Care partners' perceptions of amyloid-targeting therapy and treat-to-clearance for Alzheimer's disease in Japan: a qualitative study. Neurol Ther. 2026;15:257-267. PMID 41307609.

Non-journal sources. Organisation websites fetched 2026-08-31: Alzheimer's Disease International (https://www.alzint.org/); Dementia Alliance International (https://www.dementiaallianceinternational.org/); Alzheimer Europe (https://www.alzheimer-europe.org/); Alzheimer's Association (https://www.alz.org/); Alzheimer's Society (https://www.alzheimers.org.uk/); Alzheimer's Research UK (https://www.alzheimersresearchuk.org/); Alzheimer Society of Canada (https://alzheimer.ca/en); Dementia Australia (https://www.dementia.org.au/); 認知症の人と家族の会 (https://www.alzheimer.or.jp/); CEAFA (https://www.ceafa.es/); ABRAz (https://abraz.org.br/); DementiaSA (https://www.dementiasa.org/); ADASA (https://www.adasa.org.za/).